Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The objective of this clinical study is to evaluate the effectiveness and safety of
selegiline plus docetaxel therapy compared to the standard of care - docetaxel therapy -
among patients diagnosed with metastatic, castrate-resistant prostate adenocarcinoma.